Ryvu Therapeutics SA (RVU) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.522x

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.522x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-28.09 Million ≈ $-7.73 Million USD) by net assets (zł53.83 Million ≈ $14.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ryvu Therapeutics SA - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ryvu Therapeutics SA debt and liabilities for a breakdown of total debt and financial obligations.

Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Merafe JSE:MRF	-0.033x
Ecomate Holdings Bhd KLSE:0239	-0.103x
Detection Technology OY HE:DETEC	0.019x
Paragon Care Limited F:PXS	0.001x
Modiv Inc NYSE:MDV	0.020x
Hyundai Pharm KO:004310	-0.038x
Laramide Resources Ltd AU:LAM	-0.017x
Euroapi SAS PA:EAPI	0.018x

Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Ryvu Therapeutics SA.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł53.83 Million ≈ $14.82 Million	zł-114.10 Million ≈ $-31.40 Million	-2.119x	-135.52%
2024-12-31	zł143.88 Million ≈ $39.60 Million	zł-129.48 Million ≈ $-35.63 Million	-0.900x	-176.29%
2023-12-31	zł259.59 Million ≈ $71.44 Million	zł-84.55 Million ≈ $-23.27 Million	-0.326x	-624.62%
2022-12-31	zł343.39 Million ≈ $94.51 Million	zł21.32 Million ≈ $5.87 Million	0.062x	+118.18%
2021-12-31	zł169.42 Million ≈ $46.63 Million	zł-57.87 Million ≈ $-15.93 Million	-0.342x	-618.46%
2020-12-31	zł223.72 Million ≈ $61.57 Million	zł-10.64 Million ≈ $-2.93 Million	-0.048x	+67.28%
2019-12-31	zł119.76 Million ≈ $32.96 Million	zł-17.40 Million ≈ $-4.79 Million	-0.145x	+22.25%
2018-12-31	zł194.86 Million ≈ $53.63 Million	zł-36.42 Million ≈ $-10.02 Million	-0.187x	-208.91%
2017-12-31	zł64.00 Million ≈ $17.61 Million	zł10.98 Million ≈ $3.02 Million	0.172x	+252.23%
2016-12-31	zł55.71 Million ≈ $15.33 Million	zł-6.28 Million ≈ $-1.73 Million	-0.113x	+67.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	zł-16.43 Million ≈ $-4.52 Million	-0.350x	+33.84%
2014-12-31	zł9.25 Million ≈ $2.55 Million	zł-4.90 Million ≈ $-1.35 Million	-0.530x	+99.76%
2013-12-31	zł3.13 Million ≈ $861.02K	zł-694.94 Million ≈ $-191.26 Million	-222.129x	-13705.80%
2012-12-31	zł5.53 Million ≈ $1.52 Million	zł-8.90 Million ≈ $-2.45 Million	-1.609x	-208.42%
2011-12-31	zł11.46 Million ≈ $3.15 Million	zł-5.98 Million ≈ $-1.65 Million	-0.522x	+78.85%
2010-12-31	zł1.50 Million ≈ $413.48K	zł-3.71 Million ≈ $-1.02 Million	-2.467x	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$152.71 Million

zł554.88 Million PLN

Market Cap Rank

#17578 Global

#122 in Poland

Share Price

zł24.00

Change (1 day)

+2.56%

52-Week Range

zł20.70 - zł34.30

All Time High

zł75.00